448TiP A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)

Abstract

A new concept of ‘NeoRAS wild-type (WT)’ which means conversion of RAS status from RAS mutant to RAS WT after treatment has been reported; previous studies demonstrated the potential efficacy of epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (mCRC) patients with NeoRAS WT. Moreover, it has been suggested that gene mutational status in circulating tumor DNA (ctDNA) may be useful to define the NeoRAS WT mCRC avoiding false negative of RAS mutation and gene mutations other than RAS in ctDNA are associated with efficacy of EGFR inhibitors.